Bhasker V. Shetty

1.4k total citations
28 papers, 1.1k citations indexed

About

Bhasker V. Shetty is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Bhasker V. Shetty has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 11 papers in Virology and 10 papers in Molecular Biology. Recurrent topics in Bhasker V. Shetty's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (11 papers) and Biochemical and Molecular Research (5 papers). Bhasker V. Shetty is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (11 papers) and Biochemical and Molecular Research (5 papers). Bhasker V. Shetty collaborates with scholars based in United States, Switzerland and Japan. Bhasker V. Shetty's co-authors include Maha Kosa, Amy K. Patick, Jay F. Davies, Siegfried Reich, Krzysztof Appelt, Vincent J. Kalish, Stephanie Webber, Stephen W. Kaldor, Bruce A. Dressman and Mark A. Muesing and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Bhasker V. Shetty

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bhasker V. Shetty United States	13	476	346	327	315	178	28	1.1k
Roger D. Tung United States	24	657 1.4×	451 1.3×	468 1.4×	773 2.5×	166 0.9×	41	2.0k
Lianhong Xu United States	18	231 0.5×	146 0.4×	378 1.2×	270 0.9×	92 0.5×	42	920
Charles A. Flentge United States	9	445 0.9×	303 0.9×	233 0.7×	212 0.7×	47 0.3×	14	738
John Proudfoot United States	21	358 0.8×	258 0.7×	607 1.9×	507 1.6×	187 1.1×	54	1.5k
Stacey L. McDaniel United States	7	447 0.9×	369 1.1×	365 1.1×	289 0.9×	44 0.2×	7	863
Keith Riccardi United States	17	194 0.4×	145 0.4×	225 0.7×	349 1.1×	276 1.6×	32	949
Darren Moss United Kingdom	17	324 0.7×	148 0.4×	73 0.2×	234 0.7×	143 0.8×	30	904
Gerry Rhodes United States	11	434 0.9×	273 0.8×	87 0.3×	106 0.3×	80 0.4×	21	709
Xiao‐Jian Zhou United States	19	475 1.0×	215 0.6×	141 0.4×	213 0.7×	111 0.6×	44	1.0k
Rhonda B. Levin United States	9	527 1.1×	405 1.2×	425 1.3×	428 1.4×	52 0.3×	9	1.1k

Countries citing papers authored by Bhasker V. Shetty

Since Specialization

Citations

This map shows the geographic impact of Bhasker V. Shetty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bhasker V. Shetty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bhasker V. Shetty more than expected).

Fields of papers citing papers by Bhasker V. Shetty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bhasker V. Shetty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bhasker V. Shetty. The network helps show where Bhasker V. Shetty may publish in the future.

Co-authorship network of co-authors of Bhasker V. Shetty

This figure shows the co-authorship network connecting the top 25 collaborators of Bhasker V. Shetty. A scholar is included among the top collaborators of Bhasker V. Shetty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bhasker V. Shetty. Bhasker V. Shetty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Yamazaki, Shinji, Paolo Vicini, Zhongzhou Shen, et al.. (2011). Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models. Journal of Pharmacology and Experimental Therapeutics. 340(3). 549–557. 55 indexed citations

2.

Bu, Hai‐Zhi, William F. Pool, Ellen Y. Wu, & Bhasker V. Shetty. (2007). A Unique Example of Drug Metabolism: Tetra- and Penta-Oxygenation Reactions of Capravirine in Rats, Dogs and Humans. Drug Metabolism Letters. 1(1). 61–65. 1 indexed citations

3.

Bu, Hai‐Zhi, Ping Zhao, Ping Kang, et al.. (2007). Evaluation of Capravirine as a CYP3A Probe Substrate: In Vitro and in Vivo Metabolism of Capravirine in Rats and Dogs. Drug Metabolism and Disposition. 35(9). 1593–1602. 2 indexed citations

4.

Bu, Hai‐Zhi, William F. Pool, Ellen Y. Wu, et al.. (2004). METABOLISM AND EXCRETION OF CAPRAVIRINE, A NEW NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, ALONE AND IN COMBINATION WITH RITONAVIR IN HEALTHY VOLUNTEERS. Drug Metabolism and Disposition. 32(7). 689–698. 14 indexed citations

5.

Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(8). 2405–2405. 1 indexed citations

6.

Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(4). 1086–1093. 107 indexed citations

7.

Yuen, Geoffrey J., et al.. (1997). The pharmacokinetics of nelfinavir administered alone and with rifampin in healthy volunteers. Clinical Pharmacology & Therapeutics. 61(2). 147. 4 indexed citations

8.

Wu, Xinglin, et al.. (1997). High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 695(2). 373–380. 66 indexed citations

9.

Kaldor, Stephen W., Vincent J. Kalish, Jay F. Davies, et al.. (1997). Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. Journal of Medicinal Chemistry. 40(24). 3979–3985. 483 indexed citations

10.

Shetty, Bhasker V., et al.. (1996). Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrobial Agents and Chemotherapy. 40(1). 110–114. 50 indexed citations

11.

Webber, S. E., Charlotte A. Bartlett, Theodore J. Boritzki, et al.. (1996). AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemotherapy and Pharmacology. 37(6). 509–517. 75 indexed citations

12.

Melnick, Michael, Siegfried Reich, Anthony J. Trippe, et al.. (1996). ChemInform Abstract: Bis Tertiary Amide Inhibitors of the HIV‐1 Protease Generated via Protein Structure‐Based Iterative Design.. ChemInform. 27(43).

13.

Longer, Mark A., et al.. (1995). Preformulation Studies of a Novel HIV Protease Inhibitor, AG1343. Journal of Pharmaceutical Sciences. 84(9). 1090–1093. 35 indexed citations

14.

Longer, Mark A., et al.. (1995). Formulation development of an oral dosage form for an hiv protease inhibitor, AG1284. International Journal of Pharmaceutics. 117(2). 197–207. 2 indexed citations

15.

Shetty, Bhasker V., et al.. (1995). High-performance liquid chromatographic method for the determination of a novel thymidylate synthase inhibitor, AG 331, in human serum. Journal of Chromatography B Biomedical Sciences and Applications. 673(2). 281–288.

16.

Shetty, Bhasker V., et al.. (1994). Evaluation of Hepatic Metabolism of Salicylic Acid in Perfused Rat Liver. Journal of Pharmaceutical Sciences. 83(4). 607–608. 3 indexed citations

17.

Pavliv, Leo, et al.. (1994). Topical formulation development of a novel thymidylate synthase inhibitor for the treatment of psoriasis. International Journal of Pharmaceutics. 105(3). 227–233. 4 indexed citations

18.

Riley, Christopher M., et al.. (1993). A stability-indicating assay and the preformulation characteristics of the radiosensitizer, 1,2,4-benzotriazin-3-amine 1,4-dioxide. Journal of Pharmaceutical and Biomedical Analysis. 11(2). 131–138. 1 indexed citations

19.

Shetty, Bhasker V., et al.. (1992). Degradation of dacarbazine in aqueous solution. Journal of Pharmaceutical and Biomedical Analysis. 10(9). 675–683. 34 indexed citations

20.

Shetty, Bhasker V., et al.. (1970). Synthesis and activity of some 3-substituted 1,2,3,4-pseudooxatriazol-5-ones and their precursors and related compounds. Journal of Medicinal Chemistry. 13(2). 196–203. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact